PF-Atlas › Clinical Trials › NCT02999178
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease
Nintedanib · Phase 3
Registry ID
NCT02999178
Phase
Phase 3
Status
Completed
Drug / intervention
Nintedanib
Sponsor
Boehringer Ingelheim
Start
2017-01-17
Enrollment
663
Locations
153
About this trial
The aim of the current study is to investigate the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) defined as patients who present with features of diffuse fibrosing lung disease of \>10% extent on high-resolution computed tomography (HRCT) and whose lung function and respiratory symptoms or chest imaging have worsened despite treatment with unapproved medications used in clinical practice to treat ILD. There is currently no efficacious treatment available for PF-ILD. Based on its efficacy and safety in Idiopathic Pulmonary Fibrosis (IPF), it is anticipated that Nintedanib will be a new treatment option for patients with PF-ILD.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02999178 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.